PeptideDB

MSDC-0602K (Azemiglitazone potassium) 1314533-27-1

MSDC-0602K (Azemiglitazone potassium) 1314533-27-1

CAS No.: 1314533-27-1

MSDC-0602K(Azemiglitazone potassium) is a thiazolidinedione (Ps-TZD) that spares PPARγ; its IC50 value is 18.25 μM. Th
Data collection:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

MSDC-0602K(Azemiglitazone potassium) is a thiazolidinedione (Ps-TZD) that spares PPARγ; its IC50 value is 18.25 μM. The mitochondrial pyruvate carrier is modulated by ezemiglitazone potassium (MPC). Research on fatty liver, including abnormal lipid metabolism, inflammation, and insulin resistance, can benefit from the use of ezemiglitazone potassium[2]. Both by itself and in conjunction with ligarglutide, the insulin sensitizer acetazolamide potassium improves insulinemia and fatty liver disease in mice[3].

Physicochemical Properties


Molecular Formula C19H16KNO5S
Exact Mass 409.04
Elemental Analysis C, 55.73; H, 3.94; K, 9.55; N, 3.42; O, 19.53; S, 7.83
CAS # 1314533-27-1
Related CAS # Azemiglitazone;1133819-87-0
PubChem CID 87355566
Appearance White to off-white solid powder
Hydrogen Bond Donor Count 0
Hydrogen Bond Acceptor Count 7
Rotatable Bond Count 7
Heavy Atom Count 27
Complexity 538
Defined Atom Stereocenter Count 0
InChi Key PQCFIIIBRQVVGW-UHFFFAOYSA-M
InChi Code

InChI=1S/C19H17NO5S.K/c1-24-15-4-2-3-13(10-15)16(21)11-25-14-7-5-12(6-8-14)9-17-18(22)20-19(23)26-17;/h2-8,10,17H,9,11H2,1H3,(H,20,22,23);/q;+1/p-1
Chemical Name

potassium;5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-1,3-thiazolidin-3-ide-2,4-dione
Synonyms

MSDC 0602; MSDC0602; MSDC-0602; MSDC-0602 potassium
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.
Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets PPAR-γ (IC50 = 18.25 μM)
ln Vivo Diabetic db/db and MS-NASH mice are administered oral gavage of ezemiglitazone potassium, subcutaneous injection of ligliglutide, or a combination of zemiglitazone potassium and ligliglutide. For patients with diabetes and non-alcoholic steatohepatitis (NASH), this combination treatment may be a useful therapeutic approach.
Animal Protocol Five-week-old male db/db mice on C57BL/6J background and age/sex-matched db/+ control mice
30 mg/kg MSDC-0602K; 0.2 mg/kg Liraglutide (obtained from MedChemExpress)
MSDC-0602K gavage daily, Liraglutide s.c. injection every other day, or combined MSDC-0602K+ Liraglutide
References

[1]. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287(28):23537-48.

[2]. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis. Expert Opin Investig Drugs. 2018 Jul;27(7):631-636.

[3]. Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide. J Biol Chem. Jan-Jun 2021;296:100807.


Solubility Data


Solubility (In Vitro) DMSO: 82~250 mg/mL (200.2~610.5 mM)
Solubility (In Vivo) Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)

Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)